UNSPSC 51183704: Rivoglitazone

This classification denotes an anti-diabetic agent with the molecular formula C20H19N3O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 3A3N0634Q6, chemically known as 2,4-thiazolidinedione, 5-((4-((6-methoxy-1-methyl-1h-benzimidazol-2-yl)methoxy)phenyl)methyl)-; but more generally known as rivoglitazone, which bears US NIH Compound Identifier 3055168. The term RIVOGLITAZONE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 15 No. 3-4, 2001, List 46).

UNSPSC 51183704 Rivoglitazone is a Commodity code identifying a single pharmaceutical product, and state and local governments procure it primarily through cooperative purchasing agreements for generic multi-source pharmaceuticals distributed across participating state facilities and local government healthcare systems. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 to establish multiple contracts for generic pharmaceuticals and over-the-counter products including rivoglitazone, structured to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC). Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three authorized wholesalers, and demonstrate pricing flexibility through flat price, net price formats, or WAC-minus pricing structures. Evaluation prioritizes price competitiveness (75 percent), fixed pricing for the contract term (10 percent), compliance with administrative fee data format requirements (5 percent), electronic data interchange capability (5 percent), and agreement to a 3 percent administrative fee (5 percent).

MMCAP's procurement vehicle spans participating state and local government facilities across Minnesota and Oregon. The RFP, issued January 20, 2026 with proposals due March 26, 2026, seeks manufacturers to provide comprehensive pricing for identified pharmaceutical products with specific National Drug Codes, SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations. All products must be available in the marketplace by May 15, 2026, with awarded vendors notified to authorized wholesalers and resulting agreements effective July 1, 2026. The contract term runs two years for new responders with optional extensions at MMCAP's sole discretion, while incumbent responders' amendments align with existing agreement expiration dates through June 30, 2028. Vendors must maintain comprehensive insurance coverage including commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, and all products must comply with FDA requirements with expiration dates of at least one year from manufacture and a minimum six-month shelf life.